Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells

International Journal of Cancer

Volumn 127, Issue 1, 2010, Pages 230-238

  Desai, Dhimant ^a   Sinha, Indu ^a   Null, Kevin ^a   Wolter, William ^b   Suckow, Mark A ^b   King, Tonya ^a   Amin, Shantu ^a   Sinha, Raghu ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Celecoxib; COX 2; HIF 1 ; Hormone refractory prostate cancer; PAIII cells; Selenocoxib

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN BCL 2; PROTEIN KINASE B; SELENOCOXIB 1; UNCLASSIFIED DRUG; CYCLOOXYGENASE 1; ORGANOSELENIUM DERIVATIVE; SELENIUM; SELENOCOXIB-1; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RAT; WISTAR RAT; ADENOCARCINOMA; ANIMAL; BLOOD; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MAGNETIC RESONANCE SPECTROSCOPY; MALE; ORGANOSELENIUM COMPOUNDS; PROSTATIC NEOPLASMS; RATS; RATS, WISTAR; SELENIUM; SULFONAMIDES;

EID: 77953441260     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25033     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer. J Clin 2009;59:225-49.
2. Mike S, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 2006;18: CD005247.
3. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002; 77:219-25.
4. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006;24: 2723-8.
5. Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, Wallen E. Phase II trial of celecoxib in prostate specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 2006;12: 2172-7.
6. Carles J, Font A, Mellado B, Domenech M, Gallardo E, González- Larriba JL, Catalan G, Alfaro J, Gonzalez Del Alba A, Nogué M, Lianes P, Tello JM. Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. Br J Cancer 2007;97:1206-10.
7. Brophy JM. Cardiovascular effects of cyclooxygenase-2 inhibitors. Curr Opin Gastroenterol 2007;23:617-24.
8. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275:11397-403.
9. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS. 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for Celecoxib in prostate cancer cells. Cancer Res 2004;64:1444-51.
10. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000; 60:6045-51.
11. Sooriakumaran P, Langley SE, Laing RW, Coley HM. COX-2 inhibition: a possible role in the management of prostate cancer? J Chemother 2007;19:21-32.
12. Vadgama JV, Wu Y, Shen D, Hsia S, Block J. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. Anticancer Res 2000;20: 1391-1414.
13. Hu H, Jiang C, Ip C, Rustum YM, Lü J. Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clin Cancer Res 2005;11:2379-88.
14. Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 2002;94:1745-57.
15. Webber MM, Perez-Ripoll EA, James GT. Inhibitory effects of selenium on the growth of DU-145 human prostate carcinoma cells in vitro. Biochem Biophys Res Commun 1985;130:603-60.
16. Venkateswaran V, Klotz LH, Fleshner NE. Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res 2002;62:2540-5.
17. Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 2000;9: 1171-82.
18. Jiang C, Wang Z, Ganther H, Lu J. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 2002;1:1059-66.
19. Ghosh J. Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. Biochem Biophys Res Commun 2004;15:624-35.
20. Pinto JT, Sinha R, Papp K, Facompre ND, Desai D, El-Bayoumy K. Differential effects of naturally occurring and synthetic organoselenium compounds on biomarkers in androgen responsive and androgen independent human prostate carcinoma cells. Int J Cancer 2007;120:1410-17.
21. Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate 2006;66:1070-5.
22. Li GX, Lee HJ, Wang Z, Hu H, Liao JD, Watts JC, Combs GF, Jr, Lü J. Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 2008;29:1005-12.
23. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, Giovannucci E. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998;90:1219-24.
24. Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP, Morris JS, Comstock GW. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000;92:2018-23.
25. Nomura AM, Lee J, Stemmermann GN, Combs GF, Jr. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000;9:883-7.
26. Clark LC, Combs GF, Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL, Jr, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63.
27. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, III, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301:39-51.
28. Chang CF, Pollard M. In vitro propagation of prostate adenocarcinoma cells from rats. Invest Urol 1977;4:331-4.
29. Pollard M, Luckert PH. Transplantable metastasizing prostate adenocarcinoma in rats. J Natl Cancer Inst 1975;54:643-9.
30. Pollard M, Suckow MA. Hormonerefractory prostate cancer in the Lobund-Wistar rat. Exp Biol Med 2005;230:520-6.
31. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzene sulfonamide (SC-58635. Celecoxib). J Med Chem 1997;40: 1347-65.
32. Sinha R, Medina D. Inhibition of cdk2 kinase activity by methylselenocysteine in synchronized mouse mammary epithelial cells. Carcinogenesis 1997;18:1541-7.
33. Sohn OS, Desai DH, Das A, Rodriguez JG, Amin SG, El-Bayoumy K. Comparative excretion and tissue distribution of selenium in mice and rats following treatment with the chemopreventive agent 1,4-phenylenebis(methylene) selenocyanate. Chem Biol Interact 2005;151:193-202.
34. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr 1998;128:1845-54.
35. El-Bayoumy K, Sinha R, Pinto JT, Rivlin, RS. Cancer chemoprevention by garlic and garlic-containing sulfur and selenium compounds. J Nutr 2006;136:864S-9S.
36. Ip C, Lisk DJ, Stoewsand GS. Mammary cancer prevention by regular garlic and selenium-enriched garlic. Nutr Cancer 1992;17:279-86.
37. Ip C, Ganther HE. Comparison of selenium and sulfur analogs in cancer prevention. Carcinogenesis 1992;13: 1167-70.
38. El-Bayoumy K, Chae Y, Upadhyaya P, Ip C. Chemoprevention of mammary cancer by diallyl selenide, a novel organoselenium compound. Anticancer Res 1996;16: 2911-15.
39. Sharma A, Sharma AK, Madhunapantula SV, Desai D, Huh SJ, Mosca P, Amin S, Robertson GP. Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clin Cancer Res 2009;15: 1674-85.
40. Sharma AK, Sharma A, Desai D, Madhunapantula SV, Huh SJ, Robertson GP, Amin S. Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates. J Med Chem 2008;51: 7820-6.
41. Narayanan NK, Nargi D, Horton L, Reddy BS, Bosland MC, Narayanan BA. Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib. Prostate 2009;69:133-41.
42. Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002;94:585-91.
43. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005;11: 1999-2007.
44. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localized prostate cancer and outcome of radical treatment: a retrospective analysis of two randomized radiotherapy trials and one surgical cohort study. Lancet Oncol 2008;9:342-51.
45. Shukla S, Maclennan GT, Marengo SR, Resnick MI, Gupta S. Constitutive activation of PI3K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 2005;64:224-39.
46. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgenin-dependent prostate cancer. Cancer Res 1992;52:6940-4.
47. Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, Igawa M. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 2006;12:6116-24.